Table 1.
Patient and treatment characteristics with comparison between EFI and TNI and between stages I/II and stage III disease
| All | EFI | TNI | p-value | Stage I/II | Stage III | p-value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
# patients |
107 |
|
48 |
|
59 |
|
|
86 |
21 |
|
||
|
Age |
|
|
|
|
|
|
<0.001 |
|
|
|
|
<0.001 |
|
median/range [years] |
57 |
26 - 83 |
66 |
37 - 83 |
51 |
26 - 74 |
|
61 |
27 – 83 |
51 |
26 - 68 |
|
|
≥60 years |
48 |
45% |
35 |
73% |
13 |
22% |
|
45 |
52% |
3 |
14% |
|
|
Sex [male] |
59 |
57% |
26 |
55% |
33 |
56% |
NS |
49 |
57% |
10 |
48% |
|
|
Karnofsky Performance status |
|
|
|
|
|
|
<0.001 |
|
|
|
|
NS |
|
median/range |
90 |
50 - 100 |
90 |
50 - 100 |
100 |
80 - 100 |
|
90 |
50 – 100 |
90 |
70 – 100 |
|
|
B-Symptoms |
1 |
1% |
0 |
0% |
1 |
2% |
NS |
0 |
0% |
1 |
5% |
NS |
|
LDH |
|
|
|
|
|
|
NS |
|
|
|
|
0.03 |
|
Elevated |
16 |
15% |
9 |
19% |
7 |
12% |
|
8 |
9% |
8 |
38% |
|
|
Normal |
63 |
59% |
29 |
60% |
34 |
58% |
|
55 |
64% |
8 |
24% |
|
|
unknown |
28 |
26% |
10 |
21% |
18 |
30% |
|
23 |
27% |
5 |
38% |
|
|
Ann Arbor stage |
|
|
|
|
|
|
0.04 |
|
|
|
|
|
|
I |
50 |
47% |
27 |
56% |
23 |
39.0% |
|
|
|
|
|
|
|
II |
36 |
34% |
18 |
38% |
18 |
30.5% |
|
|
|
|
|
|
|
III |
21 |
20% |
3 |
6% |
18 |
30.5% |
|
|
|
|
|
|
|
Bulk ≥7.5 cm |
5 |
5% |
2 |
4% |
3 |
5% |
NS |
3 |
3% |
2 |
9% |
NS |
| Radiotherapy dose median/range [Gy] | 38 | 25 - 50 | 38 | 27 - 50 | 37 | 25 - 46 | NS | 37 | 25 - 50 | 37 | 29 - 46 | NS |